Large Cell Neuroendocrine Carcinoma Transformation as a Mechanism of Acquired Resistance to Osimertinib in Non-small Cell Lung Cancer: Case Report and Literature Review-Reference-Cited by-同舟云学术

Large Cell Neuroendocrine Carcinoma Transformation as a Mechanism of Acquired Resistance to Osimertinib in Non-small Cell Lung Cancer: Case Report and Literature Review

Published:2021-08 Issue: Volume: Page:
ISSN:1525-7304
Container-title:Clinical Lung Cancer
language:en
Short-container-title:Clinical Lung Cancer

Author:

Lee Matthew^ORCID,Patel Dhruv,Jofre Sebastian,Fidvi Shabnam^ORCID,Suhrland Mark,Cohen Perry,Cheng Haiying

Publisher

Elsevier BV

Subject

Cancer Research,Pulmonary and Respiratory Medicine,Oncology

Reference40 articles.

1. Frequency of the acquired resistant mutation T790 M in non-small cell lung cancer patients with active exon 19Del and exon 21 L858R: a systematic review and meta-analysis;Wang;BMC Cancer,2018

2. Osimertinib or platinum-pemetrexed in EGFR T790M-positive lung cancer;Mok;N Engl J Med,2017

3. Osimertinib in resected egfr-mutated non-small-cell lung cancer;Wu;N Engl J Med,2020

4. Overall survival with osimertinib in untreated, EGFR-mutated advanced NSCLC;Ramalingam;N Engl J Med,2020

5. Osimertinib in untreated EGFR-mutated advanced non-small-cell lung cancer;Soria;N Engl J Med,2018

Cited by 7 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. CRACD loss induces neuroendocrine cell plasticity of lung adenocarcinoma;Cell Reports;2024-06

2. Clonality Analysis for the Relationship between the Pulmonary Combined Neuroendocrine Carcinoma and “the So-Called Reported Histologic Transformation”;Cancers;2023-11-29

3. Acquired resistance mechanisms to osimertinib: The constant battle;Cancer Treatment Reviews;2023-05

4. CRACD suppresses neuroendocrinal plasticity of lung adenocarcinoma;2023-04-21

5. Targeting Oncogenic Driver Mutations in Lung Cancer;El in Molecular Onco;2023-01-12